KEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030) BeaconMedIC 13:06 6 years ago 1 617 Далее Скачать
Has the KEYNOTE-189 Trial Defined a Clear Standard of Care? (BMIC-022) BeaconMedIC 8:13 6 years ago 1 423 Далее Скачать
The KEYNOTE-189 Trial for Untreated Metastatic Nonsquamous NSCLC OncLive 10:32 4 years ago 631 Далее Скачать
The KEYNOTE-189 Trial for Untreated Metastatic Nonsquamous NSCLC OncLive 10:34 4 years ago 115 Далее Скачать
Dr. Stinchcombe on Advances in Targeted Therapies in NSCLC OncLive 1:10 6 years ago 355 Далее Скачать
KEYNOTE-189: Clinical Implications in Patients with Less Than 1% Tumor PD-L1 Expression (BMIC-033) BeaconMedIC 6:32 6 years ago 324 Далее Скачать
The KEYNOTE-189 Trial for Untreated Metastatic Nonsquamous NSCLC OncLive 10:34 4 years ago 136 Далее Скачать
KEYNOTE 189: Targeting NSCLC patients with brain and liver metastases ecancer 2:57 5 years ago 159 Далее Скачать
Dr. Rodriguez-Abreu on the Final Analysis of the KEYNOTE-189 Trial in NSCLC OncLive 1:55 4 years ago 286 Далее Скачать
Chemo-Immunotherapy in NSCLC: The KEYNOTE-189 Trial Targeted Oncology 4:53 6 years ago 147 Далее Скачать
KEYNOTE-189: Clinical Implications for High Tumor PD-L1 Expression (BMIC-031) BeaconMedIC 7:58 6 years ago 257 Далее Скачать
KEYNOTE-189: Clinical Implications in Patients with Low (1-49%) Tumor PD-L1 Expression (BMIC-032) BeaconMedIC 6:16 6 years ago 255 Далее Скачать
